 |
|
|
| |
Long-term efficacy, safety and persistence of dolutegravir/lamivudine vs bictegravir/emtricitabine/tenofovir alafenamide among virologically suppressed adults-results from the 144-week observational extension phase of the DYAD study
|
| |
| |
IAS 2026 Rio, Brazil July 26-31
|
| |
|
|
|
|
|
